- Naloxone
- Buprenorphine
- Methadone
Opioid Addiction Prevention Market size was valued at USD 3,781.1 million in 2023 and poised to grow at a CAGR of 10.7% from 2024-2030. Several factors are driving the growth of the market, the increasing prevalence of opioid addiction, increased awareness of the dangers of opioids, and regulatory changes. However, several constraints are limiting the growth of the market, such as the high cost of treatment, the lack of access to treatment, and the stigma associated with addiction. Despite the constraints, there are several opportunities for growth in the market, such as the development of new and more affordable treatment options, the expansion of access to treatment, and the development of new prevention strategies. The market is also being shaped by several trends, such as the rise of telehealth, the use of medication-assisted treatment (MAT), and the focus on prevention.
Opioid addiction is a serious problem that is affecting millions of people around the world. The Centers for Disease Control and Prevention (CDC) reports that in 2019, over 70,000 people in the United States died of a drug overdose, with opioids being involved in the majority of these deaths. Governments around the world are implementing stricter regulations on the prescribing of opioids. This is creating a demand for new pain management strategies that do not involve opioids. There is a growing awareness of the dangers of opioids, and this is leading to a demand for products and services that can help prevent addiction.
Opioid Addiction Prevention Market Key developments:
- May 2023, Indivior Announces U.S. FDA approval of OPVEE® (nalmefene) nasal spray, an opioid overdose rescue medication for natural and synthetic opioids like fentanyl.
- May 2024, FDA clears new buprenorphine treatment option, Braeburn's long-acting Brixadi to treat opioid use disorder.
Opioids Addiction Prevention Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
10.7%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Opioids Addiction Prevention Market Dynamics
With the development of new and more affordable treatment options, in the opioid addiction prevention market, there is a growing pipeline of new medications and therapies that are being developed to treat opioid addiction, and there are several initiatives underway to expand access to treatment, such as telehealth and medication-assisted treatment (MAT), growing focus on the development of new prevention strategies such as education programs and screening tools. efforts to reduce the prescribing of opioids. Telehealth is making it easier for people to access addiction treatment, especially in rural areas. MAT is a form of treatment that combines medication with counseling and behavioral therapy. MAT is very effective in treating opioid addiction.
North-America Got Significant Share
Opioids Addiction Prevention Market Regional Analysis
Based on regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America is currently the largest market for opioid addiction prevention, due to the high prevalence of opioid addiction in the region, particularly in the United States. The presence of major pharmaceutical companies and a well-established healthcare system are also contributing factors. The European market for opioid addiction prevention is also expected to grow steadily, driven by increasing government funding and initiatives to address opioid misuse. However, the market is fragmented due to the presence of various national healthcare systems and regulatory frameworks. The Asia Pacific market for opioid addiction prevention is expected to witness the fastest growth in the coming years, due to the rising burden of opioid addiction in some countries in the region, such as China and India. However, the market is still at a nascent stage, and there is a lack of awareness about opioid addiction prevention programs. The Latin American market for opioid addiction prevention is relatively small but is expected to grow in the coming years, driven by increasing government awareness about the problem of opioid addiction. The rest of the world market for opioid addiction prevention is expected to grow slowly, due to the limited resources available for addiction prevention programs in these regions.
Latin America
Europe
Asia Pacific
Middle East
North America
Opioids Addiction Prevention Market Segmentation
By Drug Type
By Treatment Centres
- Residential Treatment Centers
- Outpatient Treatment Centers
- Inpatient Treatment Centers
By Route of Administration
- Oral
- Parental
By Distribution Channel
- Retail Pharmacies
- Hospitals
- Rehabilitation Centers
Geography
- North America
- Europe
- The Asia Pacific
- Latin America
- MEA
Frequently Asked Questions
The opioid addiction prevention market was valued at USD 3,781.1 million in 2023 and growing at a CAGR of 10.7%.
Several factors are driving the growth of the market, the increasing prevalence of opioid addiction, increased awareness of the dangers of opioids, and regulatory changes
Alkermes, AstraZeneca Plc., BioDelivery Sciences International Inc., Braeburn, Camurus, Cerebral, Dr. Reddy, Hikma Pharmaceuticals PLC, Indivior PLC, Mallinckrodt Pharmaceuticals, NYC Health + Hospitals, Orexo AB, Pear Therapeutics, Pfizer, and Reckitt Benckiser Pharmaceuticals Inc.
Market research is segmented based on drug type, treatment centers, route of administration, distribution channels, end-users, and region.
North America is dominant in the opioid addiction prevention market.
Key Features of the Reports
- The opioids addiction prevention market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
| 1. Executive Summary |
| 2. Global Opioids Addiction Prevention Market Introduction |
| 2.1. Global Opioids Addiction Prevention Market Taxonomy |
| 2.2. Global Opioids Addiction Prevention Market Definitions |
| 2.2.1. Drug Type |
| 2.2.2. Treatment Centers |
| 2.2.3. Route of Administration |
| 2.2.4. Distribution Channel |
| 2.2.5. Region |
| 3. Global Opioids Addiction Prevention Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Opioids Addiction Prevention Market Dynamic Factors - Impact Analysis |
| 3.6. Impact of COVID 19 on The Market |
| 3.7. Three Forecast Scenarios - Pessimistic, Conservative and Opportunistic |
| 3.8. Mapping Market Players Activities |
| 3.9. Recent Key Developments |
| 3.10. Financial Status of the Market Players |
| 3.11. Recent Acquisitions, Collaborations and Mergers |
| 4. Global Opioids Addiction Prevention Market Analysis, 2019-2023 and Forecast, 2024-2030 |
| 4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Opioids Addiction Prevention Market Forecast, By Drug Type, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 5.1. Naloxone |
| 5.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Buprenorphine |
| 5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Methadone |
| 5.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Opioids Addiction Prevention Market Forecast, By Treatment Centers, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 6.1. Residential Treatment Centers |
| 6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Outpatient Treatment Centers |
| 6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Inpatient Treatment Centers |
| 6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Market Opportunity Analysis Global Opioids Addiction Prevention Market Forecast, By Route of Administration, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 7.1. Oral |
| 7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Parental |
| 7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8. Market Opportunity Analysis Global Opioids Addiction Prevention Market Forecast, By Distribution Channel, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 8.1. Retail Pharmacies |
| 8.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Hospitals |
| 8.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Rehabilitation Centers |
| 8.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9. Global Opioids Addiction Prevention Market Forecast, By Region, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia-Pacific |
| 9.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Latin America |
| 9.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Middle East and Africa |
| 9.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 9.6. Global Opioids Addiction Prevention Market - Opportunity Analysis Index, By Drug Type, Treatment Centers, Route of Administration, Distribution Channel, and Region, 2024-2030 |
| 10. North America Opioids Addiction Prevention Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 10.1. Drug Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Naloxone |
| 10.1.2. Buprenorphine |
| 10.1.3. Methadone |
| 10.2. Treatment Centers Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Residential Treatment Centers |
| 10.2.2. Outpatient Treatment Centers |
| 10.2.3. Inpatient Treatment Centers |
| 10.3. Route of Administration Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Oral |
| 10.3.2. Parental |
| 10.4. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1. Retail Pharmacies |
| 10.4.2. Hospitals |
| 10.4.3. Rehabilitation Centers |
| 10.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 10.5.1. U.S. |
| 10.5.2. Canada |
| 10.6. North America Opioids Addiction Prevention Market - Opportunity Analysis Index, By Drug Type, Route of Administration and Country, 2024-2030 |
| 10.7. North America Opioids Addiction Prevention Market Dynamics Trends |
| 11. Europe Opioids Addiction Prevention Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 11.1. Drug Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 11.1.1. Naloxone |
| 11.1.2. Buprenorphine |
| 11.1.3. Methadone |
| 11.2. Treatment Centers Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Residential Treatment Centers |
| 11.2.2. Outpatient Treatment Centers |
| 11.2.3. Inpatient Treatment Centers |
| 11.3. Route of Administration Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Oral |
| 11.3.2. Parental |
| 11.4. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Retail Pharmacies |
| 11.4.2. Hospitals |
| 11.4.3. Rehabilitation Centers |
| 11.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 11.5.1. Germany |
| 11.5.2. UK |
| 11.5.3. France |
| 11.5.4. Italy |
| 11.5.5. Spain |
| 11.5.6. Rest of Europe |
| 11.6. Europe Opioids Addiction Prevention Market - Opportunity Analysis Index, By Drug Type, Route of Administration and Country, 2024-2030 |
| 11.7. Europe Opioids Addiction Prevention Market Dynamics Trends |
| 12. Asia-Pacific Opioids Addiction Prevention Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 12.1. Drug Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 12.1.1. Naloxone |
| 12.1.2. Buprenorphine |
| 12.1.3. Methadone |
| 12.2. Treatment Centers Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Residential Treatment Centers |
| 12.2.2. Outpatient Treatment Centers |
| 12.2.3. Inpatient Treatment Centers |
| 12.3. Route of Administration Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Oral |
| 12.3.2. Parental |
| 12.4. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Retail Pharmacies |
| 12.4.2. Hospitals |
| 12.4.3. Rehabilitation Centers |
| 12.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 12.5.1. Japan |
| 12.5.2. China |
| 12.5.3. India |
| 12.5.4. ASEAN |
| 12.5.5. Rest of Asia-Pacific |
| 12.6. Asia-Pacific Opioids Addiction Prevention Market - Opportunity Analysis Index, By Drug Type, Route of Administration and Country, 2024-2030 |
| 12.7. Asia-Pacific Opioids Addiction Prevention Market Dynamics Trends |
| 13. Latin America Opioids Addiction Prevention Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 13.1. Drug Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 13.1.1. Naloxone |
| 13.1.2. Buprenorphine |
| 13.1.3. Methadone |
| 13.2. Treatment Centers Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 13.2.1. Residential Treatment Centers |
| 13.2.2. Outpatient Treatment Centers |
| 13.2.3. Inpatient Treatment Centers |
| 13.3. Route of Administration Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Oral |
| 13.3.2. Parental |
| 13.4. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Retail Pharmacies |
| 13.4.2. Hospitals |
| 13.4.3. Rehabilitation Centers |
| 13.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 13.5.1. Brazil |
| 13.5.2. Argentina |
| 13.5.3. Rest of Latin America |
| 13.6. Latin America Opioids Addiction Prevention Market - Opportunity Analysis Index, By Drug Type, Route of Administration and Country, 2024-2030 |
| 13.7. Latin America Opioids Addiction Prevention Market Dynamics Trends |
| 14. Middle East and Africa Opioids Addiction Prevention Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Million) |
| 14.1. Drug Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 14.1.1. Naloxone |
| 14.1.2. Buprenorphine |
| 14.1.3. Methadone |
| 14.2. Treatment Centers Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 14.2.1. Residential Treatment Centers |
| 14.2.2. Outpatient Treatment Centers |
| 14.2.3. Inpatient Treatment Centers |
| 14.3. Route of Administration Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 14.3.1. Oral |
| 14.3.2. Parental |
| 14.4. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 14.4.1. Retail Pharmacies |
| 14.4.2. Hospitals |
| 14.4.3. Rehabilitation Centers |
| 14.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 14.5.1. Saudi Arabia |
| 14.5.2. GCC Countries |
| 14.5.3. South Africa |
| 14.5.4. Rest of MEA |
| 14.6. MEA Opioids Addiction Prevention Market - Opportunity Analysis Index, By Drug Type, Route of Administration and Country, 2024-2030 |
| 14.7. MEA Opioids Addiction Prevention Market Dynamics Trends |
| 15. Competition Landscape |
| 15.1. Strategic Dashboard of Top Market Players |
| 15.2. Company Profiles (Introduction, Financial Analysis, Drug Type Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 15.2.1. Omeros |
| 15.2.2. Camurus |
| 15.2.3. Orexo |
| 15.2.4. MediciNova |
| 15.2.5. Teva Pharmaceuticals |
| 15.2.6. Hikma Pharmaceuticals |
| 15.2.7. Reckitt Benckiser Pharmaceuticals, Inc. |
| 15.2.8. Mylan |
| 15.2.9. Dr. Reddy's Laboratories |
| 15.2.10. Addinex Technologies, Inc. |
| 15.2.11. Indivior |
| 15.2.12. Alkermes |
| 15.2.13. Titan Pharmaceuticals |
| 16. Research Methodology |
| 17. Key Assumptions and Acronyms |
- Alkermes
- AstraZeneca Plc.
- BioDelivery Sciences International Inc.
- Braeburn
- Camurus
- Cerebral
- Dr. Reddy
- Hikma Pharmaceuticals PLC
- Indivior PLC
- Mallinckrodt Pharmaceuticals
- NYC Health + Hospitals
- Orexo AB
- Pear Therapeutics
- Pfizer
- Reckitt Benckiser Pharmaceuticals Inc.